PRME NASDAQ
Cambridge, MA 02139
US
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor proteinâa hybrid composed of a Cas protein and a reverse transcriptase enzymeâwith a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Chung Wendy | A-Award | 75,000 | $3.06 | 2026-06-05 |
| Cahill Thomas | A-Award | 75,000 | $3.06 | 2026-06-05 |
| Schenkein David P | A-Award | 75,000 | $3.06 | 2026-06-05 |
| Marrazzo Jeffrey D | A-Award | 75,000 | $3.06 | 2026-06-05 |
| NELSEN ROBERT | A-Award | 75,000 | $3.06 | 2026-06-05 |